These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

286 related items for PubMed ID: 16235978

  • 21. Eplerenone improves prognosis in postmyocardial infarction diabetic patients with heart failure: results from EPHESUS.
    O'Keefe JH, Abuissa H, Pitt B.
    Diabetes Obes Metab; 2008 Jun; 10(6):492-7. PubMed ID: 17490427
    [Abstract] [Full Text] [Related]

  • 22. Cost-Effectiveness of Eplerenone Compared to Usual Care in Patients With Chronic Heart Failure and NYHA Class II Symptoms, an Australian Perspective.
    Ademi Z, Pasupathi K, Liew D.
    Medicine (Baltimore); 2016 May; 95(18):e3531. PubMed ID: 27149456
    [Abstract] [Full Text] [Related]

  • 23. Cost-effectiveness of eplerenone plus standard treatment compared with standard treatment in patients with myocardial infarction complicated by left ventricular systolic dysfunction and heart failure in the Netherlands.
    van Genugten ML, Weintraub WS, Zhang Z, Voors AA.
    Neth Heart J; 2005 Nov; 13(11):393-400. PubMed ID: 25696430
    [Abstract] [Full Text] [Related]

  • 24. Cost-effectiveness of eplerenone in patients with systolic heart failure and mild symptoms.
    Lee D, Wilson K, Akehurst R, Cowie MR, Zannad F, Krum H, van Veldhuisen DJ, Vincent J, Pitt B, McMurray JJ, Eplerenone in Mild Patients Hospitalization And Survival Study in Heart Failure (EMPHASIS-HF) Study.
    Heart; 2014 Nov; 100(21):1681-7. PubMed ID: 24993605
    [Abstract] [Full Text] [Related]

  • 25. Randomized, double-blind, multicenter, placebo-controlled study evaluating the effect of aldosterone antagonism with eplerenone on ventricular remodeling in patients with mild-to-moderate heart failure and left ventricular systolic dysfunction.
    Udelson JE, Feldman AM, Greenberg B, Pitt B, Mukherjee R, Solomon HA, Konstam MA.
    Circ Heart Fail; 2010 May; 3(3):347-53. PubMed ID: 20299607
    [Abstract] [Full Text] [Related]

  • 26. The cardiovascular effects of eplerenone, a selective aldosterone-receptor antagonist.
    Davis KL, Nappi JM.
    Clin Ther; 2003 Nov; 25(11):2647-68. PubMed ID: 14693297
    [Abstract] [Full Text] [Related]

  • 27. Eplerenone reduces mortality 30 days after randomization following acute myocardial infarction in patients with left ventricular systolic dysfunction and heart failure.
    Pitt B, White H, Nicolau J, Martinez F, Gheorghiade M, Aschermann M, van Veldhuisen DJ, Zannad F, Krum H, Mukherjee R, Vincent J, EPHESUS Investigators.
    J Am Coll Cardiol; 2005 Aug 02; 46(3):425-31. PubMed ID: 16053953
    [Abstract] [Full Text] [Related]

  • 28. Extracellular cardiac matrix biomarkers in patients with acute myocardial infarction complicated by left ventricular dysfunction and heart failure: insights from the Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study (EPHESUS) study.
    Iraqi W, Rossignol P, Angioi M, Fay R, Nuée J, Ketelslegers JM, Vincent J, Pitt B, Zannad F.
    Circulation; 2009 May 12; 119(18):2471-9. PubMed ID: 19398668
    [Abstract] [Full Text] [Related]

  • 29. Cost-Effectiveness Analysis of Patiromer and Spironolactone Therapy in Heart Failure Patients with Hyperkalemia.
    Bounthavong M, Butler J, Dolan CM, Dunn JD, Fisher KA, Oestreicher N, Pitt B, Hauptman PJ, Veenstra DL.
    Pharmacoeconomics; 2018 Dec 12; 36(12):1463-1473. PubMed ID: 30194623
    [Abstract] [Full Text] [Related]

  • 30. Candesartan cilexetil: a pharmacoeconomic review of its use in chronic heart failure and hypertension.
    Plosker GL, Keam SJ.
    Pharmacoeconomics; 2006 Dec 12; 24(12):1249-72. PubMed ID: 17129078
    [Abstract] [Full Text] [Related]

  • 31. Evaluation of eplerenone in the subgroup of EPHESUS patients with baseline left ventricular ejection fraction <or=30%.
    Pitt B, Gheorghiade M, Zannad F, Anderson JL, van Veldhuisen DJ, Parkhomenko A, Corbalan R, Klug EQ, Mukherjee R, Solomon H, EPHESUS Investigators.
    Eur J Heart Fail; 2006 May 12; 8(3):295-301. PubMed ID: 16504579
    [Abstract] [Full Text] [Related]

  • 32. Integrating traditional and emerging treatment options in heart failure.
    Nolan PE.
    Am J Health Syst Pharm; 2004 May 01; 61 Suppl 2():S14-22. PubMed ID: 15160834
    [Abstract] [Full Text] [Related]

  • 33. Clopidogrel: a pharmacoeconomic review of its use in patients with non-ST elevation acute coronary syndromes.
    Lyseng-Williamson KA, Plosker GL.
    Pharmacoeconomics; 2006 May 01; 24(7):709-26. PubMed ID: 16802846
    [Abstract] [Full Text] [Related]

  • 34. New treatment option for heart failure patients: eplerenone.
    Southworth MR, Cavallari LH.
    J Cardiovasc Nurs; 2004 May 01; 19(6):390-5. PubMed ID: 15529060
    [Abstract] [Full Text] [Related]

  • 35. Expanding the outcomes in clinical trials of heart failure: the quality of life and economic components of EPHESUS (EPlerenone's neuroHormonal Efficacy and SUrvival Study).
    Spertus JA, Tooley J, Jones P, Poston C, Mahoney E, Deedwania P, Hurley S, Pitt B, Weintraub WS.
    Am Heart J; 2002 Apr 01; 143(4):636-42. PubMed ID: 11923800
    [Abstract] [Full Text] [Related]

  • 36. Eplerenone: the evidence for its place in the treatment of heart failure after myocardial infarction.
    Nadin C.
    Core Evid; 2005 Apr 01; 1(2):125-41. PubMed ID: 22500149
    [Abstract] [Full Text] [Related]

  • 37. A pharmacoeconomic evaluation of the effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes in Spain.
    Gómez-Gerique JA, Casciano R, Stern L, Rejas J.
    Eur J Health Econ; 2004 Oct 01; 5(3):278-84. PubMed ID: 15714350
    [Abstract] [Full Text] [Related]

  • 38. Eplerenone survival benefits in heart failure patients post-myocardial infarction are independent from its diuretic and potassium-sparing effects. Insights from an EPHESUS (Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study) substudy.
    Rossignol P, Ménard J, Fay R, Gustafsson F, Pitt B, Zannad F.
    J Am Coll Cardiol; 2011 Nov 01; 58(19):1958-66. PubMed ID: 22032706
    [Abstract] [Full Text] [Related]

  • 39. Eplerenone is not superior to older and less expensive aldosterone antagonists.
    Chatterjee S, Moeller C, Shah N, Bolorunduro O, Lichstein E, Moskovits N, Mukherjee D.
    Am J Med; 2012 Aug 01; 125(8):817-25. PubMed ID: 22840667
    [Abstract] [Full Text] [Related]

  • 40. Cost-effectiveness of clopidogrel in myocardial infarction with ST-segment elevation: a European model based on the CLARITY and COMMIT trials.
    Berg J, Lindgren P, Spiesser J, Parry D, Jönsson B.
    Clin Ther; 2007 Jun 01; 29(6):1184-202. PubMed ID: 17692733
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 15.